Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA delays Capricor's deramiocel PDUFA date to review new data

The FDA is pushing back its decision on Capricor Therapeutics’ problematic Duchenne muscular dystrophy therapy to review additional data for a more niche indication. The company on Monday said the agency has extended the PDUFA ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at endpoints.news →

More in Health & Medicine

More from Monday 24 August →